

CURRICULUM VITAE

Name: Barbara Hedgis McGovern, M.D.
Associate Professor
Tufts University School of Medicine
Division of Infectious Diseases
Lemuel Shattuck Hospital
170 Morton Street
Jamaica Plain, MA 02130
781-392-2419
bmcgovern@tuftsmedicalcenter.org
Fax: (617) 971-3853

Education:

1977 B.A. in Music
Major instrument voice; minor instrument classical guitar
Queens College, CUNY

1980-84 Pre-medical coursework
Queens College, CUNY

1988 M.D.
Albert Einstein College of Medicine

Postdoctoral Training:

1988-89 Internship in Medicine, New England Medical Center, Boston, MA

1989-91 Residency in Medicine, New England Medical Center, Boston, MA

1992-95 Fellowship in Infectious Diseases, New England Medical Center

Licensure and Certification:

1988 Massachusetts Medical License: MD # (b) (6)

1991, 2001 Diplomate – American Board of Internal Medicine

1997, 2001 Diplomate – American Board of Internal Medicine, Subspecialty of Infectious Diseases

Academic Appointments:

- 1995-2006 Assistant Professor of Medicine, Tufts University School of Medicine, Boston, MA
- 2007- present Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA

Hospital Appointments:

- 1995-1997 Attending Physician, Division of Infectious Diseases, St. Elizabeth's Medical Center, Boston, MA
- 1997-2004 Attending Physician, Division of Infectious Diseases, New England Medical Center, Boston, MA
- 1997-present Attending Physician, Division of Infectious Diseases Lemuel Shattuck Hospital, Boston, MA
- 1999-2001 Vice President of Medical Staff, Lemuel Shattuck Hospital
- 1999-present Director, Hepatitis Clinic, Lemuel Shattuck Hospital

Awards and Honors:

- 1977  (b) (6)
- 1977 Graduated Magna Cum Laude, Queens College, CUNY
- 1990 Two successive Clinical Teaching Awards from 1990 and 1991 graduating classes of Tufts University School of Medicine
- 1996 St. Luke's Award for outstanding work in medical education Department of Medicine, St. Elizabeth's Medical Center
- 2002 Ray of Hope Award: Presented by Ruah's House for dedicated work with incarcerated HIV-infected women in MCI Framingham since 1998
- 2005 Award for teaching excellence from Primary Care Residency Program, Massachusetts General Hospital

- 2010 Nominated for the HIV Clinical Mentor Award, HIV Medicine Association
- 2011 Nominated for the HIV Clinical Mentor Award, HIV Medicine Association

Hospital Committee Assignments:

- 1999-2002 Member, Curriculum Committee, Tufts University School of Medicine

National and Regional Committee Assignments:

- 1999-2005 Member, Hepatitis C Advisory Panel, Massachusetts Department of Public Health
- 2007 Member, US Public Health Service Task Force Guideline Committee: Hepatitis B Treatment in the HIV-infected patient
- 2007-present Member, National Advisory Committee, Academic and Health Policy Conference on Correctional Health Care
- 2009 Member, Antiviral Advisory Committee, Food and Drug Administration
- 2010 Member, US Public Health Service Task Force Guideline Committee: Hepatitis C Treatment in the HIV-infected patient
- Peer reviewer for abstracts submitted to the 4th Annual Academic and Health Policy Conference on Correctional Health, March 10-11, 2011 in Boston, MA

Training of Fellows:

- 1999-2001  (b) (6)
- 1999-present Weekly instruction of infectious disease fellows rotating through the Viral Hepatitis Clinic at Lemuel Shattuck Hospital since its inception in 1999; Cover clinical management of HIV-infected and HIV-uninfected patients with viral hepatitis, drug-associated hepatotoxicity, hepatic steatosis; also take interested students, residents or fellows to prison clinic on request.

Teaching Responsibilities:

- 1995-1996 Organized antibiotic lecture series for housestaff
St. Elizabeth's Medical Center
- 1997-1998 Instructor in group sessions in Physical Diagnosis course at Tufts-New
England Medical Center
- 1998-present Lecturer, Tufts University School of Medicine
Pharmacology Course
Sexually Transmitted Diseases Course
- 2001-present Lecturer, Tufts University School of Medicine
HIV Pathogenesis Course
- 2001-present Didactic lectures for fellows on HCV, HBV
- 2004-present Salaried preceptorship for primary care residents from Massachusetts
General Hospital rotating through Viral Hepatitis Clinic; Also host visitors
from surrounding hospitals (eg, Baystate Medical Center, Lahey Clinic)
during clinical rotations.
- 2005-present Lecturer, Tufts University School of Medicine
Hepatitis A, B, and C Course

Professional Societies:

- 1988 American Medical Association
- 1992 Member, American College of Physicians
- 1995 Associate, American College of Physicians
- 1995 Member, Massachusetts Infectious Diseases Society
- 1996 Member, Infectious Diseases Society of America
- 2003 Member, American Association for the Study of Liver Disease
- 2004 Member, American Academy of HIV Medicine
- 2007 Member, Society of Correctional Physicians

Associate Editor, Clinical Infectious Diseases

2007-present Function as Associate Editor for all manuscripts pertaining to viral hepatitis, drug toxicity, fatty liver disease; Currently directing new initiative to increase coverage of HCV infection within the journal by facilitating special supplements and series of editorials and papers geared to increasing interest in liver disease in the ID community.

Deputy Editor for UpToDate, Infectious Disease Section

2004-present Responsible for all content pertaining to HIV, other viruses, and sexually transmitted diseases; work on weekly basis with Editors-In-Chief (b) (6), (b) (6), MD, Massachusetts General Hospital and (b) (6), MD, Johns Hopkins Medical Center. Recruit world-renown authors for all new topics and edit and re-write all content. All content then graded according to GRADE guidelines. Also attend monthly conferences on grading by Evidence-Based Medicine expert, (b) (6), originator of GRADE.

Major Clinical Research Interests

Liver disease in the HIV-infected host, including hepatitis B, hepatitis C, steatohepatitis and drug injury

Research Support

U19 Acute Hepatitis C grant awarded to Bruce Walker and colleagues 2005
Funded by the National Institutes of Health

The major goal of this grant is to study the clinical manifestations and immunologic and virologic outcomes of patients with acute hepatitis C in two different cohorts: men who have sex with men (Brazil) and recently incarcerated injection drug users (Massachusetts).

Role: Consultant since 2005 to present; several papers on cohort published to date

(b) (4)

Hepatitis C and Hepatotoxicity in HIV Infected Persons 2001
Funded by the Massachusetts Department of Public Health

The major goal of this grant was to determine the incidence of hepatotoxicity in HIV infected patients with or without Hepatitis C infection.

(b) (4)

Manuscript Reviewer:

| | |
|------|---|
| 2001 | Clinical Infectious Diseases |
| 2004 | Journal of Acquired Immune Deficiency Syndromes |
| 2006 | Antiviral Therapy |
| 2006 | Journal of Infectious Diseases |
| 2008 | JAMA |
| | Archives of Internal Medicine |
| | Hepatology |
| 2009 | Gastroenterology |
| | AIDS |
| | Lancet Infectious Diseases |
| | Lancet |
| 2010 | PLoS One |

External Reviewer for special edition of Lancet

Served as External Reviewer for special Lancet supplement on “Medical Consequences of Injection Drug Use” during a two-day editorial meeting at the London headquarters of The Lancet; the completed supplement was presented at a major session at the International AIDS conference in Vienna, July 2010.

Reviewer for the American Board of Internal Medicine

| | |
|------|--|
| 2004 | Reviewed and critiqued proposed questions for the infectious diseases board exams. |
|------|--|

BIBLIOGRAPHY

Chapters:

1. B. McGovern and K. Sherman; UpToDate 2005 – present;
Treatment and prevention of hepatitis B in the HIV-infected patient
2. B. McGovern and K. Sherman; UpToDate 2005 – present;
Epidemiology, clinical manifestations and diagnosis of HBV in the HIV-infected patient
3. B. McGovern; UpToDate 2003 – present;
Epidemiology, natural history and diagnosis of hepatitis C in the HIV-infected patient
4. B. McGovern; UpToDate 2003 – present;
Management and treatment of hepatitis C in the HIV-infected patient

5. Zakim and Boyer's Hepatology: Textbook of Liver Diseases
HIV-associated Drug Toxicity, 2011

Manuscripts

1. Bica I, **McGovern B**, Dhar R, Stone D, Katherine M, Scheib R, Snyderman D. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. *Clin Infect Dis* 2001; 32:492-7.
2. Tanios MA, Kogelman L, **McGovern B**, Hassoun PM. Acute respiratory distress syndrome complicating *Plasmodium vivax malaria*. *Critical Care Medicine* 2001; 29(3):665-667.
3. **McGovern B**, Bica I. Risk of HAART therapy in Hepatitis C. *Hepatology* 2002; 35(3):730.
4. **McGovern B**. "Management of the HIV/HCV co-infected patient: a case history and discussion". *AIDS Patient Care and STDs* 2002;16(7):319-26.
5. Stone DR, Corcoran C, Wurcel A, **McGovern B**, Quirk J, Brewer A, Sutton L, D'Aquila RT. Antiretroviral drug resistance mutations in antiretroviral naïve prisoners. *Clin Infect Dis* 2002; 35(7):883-6
6. Day CL, Lauer GM, Robbins GK, **McGovern B**, Wurcel AG, Gandhi RT, Chung RT, Walker BD. Broad specificity of virus specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. *J Virology* 2002;76; 12584-95.
7. Gandhi RT, Wurcel A, Lee H, **McGovern B**, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus-infected individuals. *Clin Infect Dis* 2003; 36:1602-5.
8. **McGovern B** and Bica I. Should the treatment of hepatitis C in HIV-seropositive and HIV-seronegative hemophiliacs include the use of induction doses of interferon? *Clin Infect Dis* 2003; 37(3): 464-5.
9. Gandhi, R.T., Wurcel, A. **McGovern, B.** Lee, H. Shopis, J. et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. *JAIDS* 2003; 34(4):439-41.
10. **McGovern, B.** Hepatic safety and HAART. *Journal of the International Association of Physicians in AIDS Care (JIAPAC)* 2004; 3(2):S23-40.

11. **McGovern B**, Fiore, J, Wurcel, A, et al. Treatment of hepatitis C in incarcerated HIV-infected patients. *Clinical Infectious Diseases* 2005; 41:S56-62 (*editorial commentary by David Thomas*).
12. Gandhi R, Wurcel A, Lee H, **McGovern, B**, et al. Response to hepatitis B vaccine in HIV-seropositive subjects with isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies. *Journal of Infectious Diseases* 2005; 191(9):1435-41
13. Schulze zur Wiesch, J, Lauer G.M, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, Allen TM, **McGovern B**, Lewis-Ximenez L, Sidney J, Sette A, Chung RT, Walker BD. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. *Journal of Immunology* 2005; 175(6):3603-13.
14. **McGovern B**, Ditelberg J, Taylor L, et al. Hepatic steatosis is associated with fibrosis, nucleoside analog use and hepatitis C genotype 3 infection in HIV-seropositive patients *Clin Infect Dis* 2006; 43:365-72 (*with editorial commentary by Andrew Talal*).
15. **McGovern B**, Wurcel A, Kim, A, et al. Acute hepatitis C in incarcerated patients 2006; *Clin Infect Dis* 2006; 42:1663-1670 (*with editorial commentary by David Thomas*).
16. **McGovern B**, Golan Y, Pratt D, et al. The impact of advanced liver disease on T-cell subsets. *Clin Infect Dis* 2007; 44:431 (*with editorial commentary by Raj Gandhi*).
17. **McGovern B**, Letter to the Editor: "Antiretroviral Therapy for Hepatitis B in HIV-infected patients". *Clin Infect Dis* 2007; 44(7):1012-3; author reply 1013, 2007 Apr 1.
18. **McGovern, B**. Hepatitis B Coinfection in HIV-infected patients: Epidemiology, natural history of disease and immunization *Antiviral Therapy* 2007;12 Suppl 3:H3-13.
19. Soriano V, Rockstroh J, Puoti M, Barreiro P, **McGovern, B**. Antiretroviral therapy and hepatotoxicity. *AIDS* 2008; 22:1-13.
20. **McGovern, B**. Hepatitis C in the HIV-infected Patient. *J Acquired Immunodeficiency Syndromes* 2007; 45:S57-S65.
21. **McGovern BH, Birch CE, Zaman MT, Bica I, Stone D, Quirk JR, Davis B, Zachary K, Basgoz N, Graeme-Cook F, and Gandhi RT**. Managing symptomatic drug-induced liver injury in HIV/Hepatitis C coinfecting patients: a role for interferon. *Clinical Infectious Diseases* 2007;45:1386-1392.

22. **McGovern, BH.** A golden opportunity: The treatment of hepatitis C in HIV-infected inmates. *Journal of Addictive Diseases* 2008; 27:69-73.
23. **McGovern, BH,** Dayyeh, BK, Chung, RT. Avoiding therapeutic pitfalls: The rationale use of specifically targeted agents against hepatitis C infection. *Hepatology* 2008; 48:1700-1712.
24. **McGovern, BH,** Nagami, E, Birch, C, et al. High rates of sustained virologic responses in acute hepatitis C virus infection are associated with low HCV RNA levels and rapid virologic response. *Journal of Infectious Diseases*; 2009; 200:877-81
25. **McGovern, BH,** Birch, C, Nagami, E, et al. Improving the diagnosis of acute hepatitis C infection using expanded viral load criteria, *Clinical Infectious Diseases* 2009; 49:1051-60.
26. Forrester JE, **McGovern BH,** Rhee MS, Sterling, RK. The individual and combined influence of HIV and hepatitis C virus on dyslipidemia in a high risk Hispanic population. *HIV Medicine* 2009; 10: 555-563.
27. Treatment of hepatitis C genotype 1 infection in HIV-infected patients on methadone maintenance. Taylor LE, Bowman S, Chapman S, Zaller N, Stein M, Cioe P, Maynard M, and **B.H. McGovern.** *Drug, Alcohol, and Dependence* 2011; 116:233-7.
28. A one-two punch to HCV seroconversion. Nagami E, Bowen M, Kim AY, **McGovern BH.** *Clin Infect Dis* 2011; 52:361-3.
29. Syphilis negatively influences hepatitis C treatment responses. Nagami E, Kim A, Baden R, **McGovern BH.** *In submission to Lancet Infectious Diseases.*
30. Eltrombopag: role in the treatment of hepatitis C virus in the HIV-infected patient with cirrhosis. Nagami E and **McGovern BH.** *In submission to J Hepatology.*
31.  (b) (4)
32. Schulz zur Weisch J, Ciuffreda D, Lewis-X L, Kasprowicz V, Nolan B, Streeck H, Aneja J, Reyor L, Allen T, Lohse A, **McGovern BH,** Chung RT, Kim A, Lauer G. Broadly directed CD4+T-cells are primed during acute HCV infection, but rapidly disappear from the blood with viral persistence. *J. Exp Med* 2011; *in press.*

Invited Editorial Commentary

Invited Editorial Commentary: What Drives HBV Related Hepatic Flares? Virus, T cells – or a Bit of Both? Clin Infect Dis; 2004; 39(1):133-135.

Hepatic steatosis in HIV/HCV coinfecting patients: Time to re-evaluate!
Gastroenterology 2011; 140:772-5.

Invited commentary: Treatment of an HIV/HCV coinfecting patient with triple therapy; Journal/ WATCH: AIDS Clinical Care 2011

Letters

1. McGovern BH, Kim A, Lauer, G. Acute hepatitis C in injection drug users. Gastroenterology 2009;

Abstracts:

1. **Mc Govern B**, Androphy E, Goodman AK, Lieberman J. Human T-cell responses to human papilloma virus type 16 in patients with cervical dysplasia and HPV-16 infection. J. Cell. Biochem. S18B, Abstract J250, 137 (1994).
2. **McGovern B**, Bica I, Stone D, Snyderman D. Increasing mortality from end-stage liver disease secondary to hepatitis C in patients with HIV [abstract 235]. In: Program and Abstracts of the 37th Conference of the Infectious Diseases Society of America (Philadelphia) 1999.
3. Murphy M, Nasraway S, **McGovern B**. Pneumococcal necrotizing fasciitis in a rheumatoid arthritis patient on etanercept [Abstract 201999]. In: Program and Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco) 2001.
4. **McGovern B**, Bica I, Bradley M, Galvin S, et al. The complexities of managing HIV/HCV co-infection in a public health clinic serving community and incarcerated patients [Abstract 520]. In: Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago) 2002.
5. **McGovern B**, Bica I, Bradley M, Susan G, et al. Obstacles to the evaluation and management of hepatitis C in a multi-ethnic underserved population of HIV seropositive patients. Hepatology 2002; 36(4):572A.
6. **McGovern B**, Rappaport E, Dhar R, McKee K, et al. Risk of hepatotoxicity in incarcerated HIV-seropositive patients with underlying hepatitis C infection

- [Abstract]. In: Program and Abstracts of the National Commission on Correctional Health Care (NCCHC) (Nashville) 2002.
7. Wurcel A, Bica I, Gandhi R, Bradley M, Galvin S, Kim A, Corcoran C, Timm J, **McGovern B**. Acute hepatitis C (HCV) in incarcerated patients with a history of intravenous drug use [Abstract 592]. In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego) 2003.
 8. **McGovern B**, Lopez M, Yoav G, Lawton A, Moore G, Pratt D, Epstein M, Knox T. Absolute CD4 T-cell subsets are decreased in HIV-seronegative patients with cirrhosis [Abstract 603]. In: Program and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego) 2003.
 9. Bica I, McGovern, B Sidhartha Pan Chung T, Ucci A, Quirk, J, Bradley M, Galvin S, Perrone R. Renal dysfunction in HIV/HCV co-infected patients receiving interferon (IFN) and ribavirin (RBV) [Abstract 593]. In: Program and Abstracts at the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego) 2003.
 10. **McGovern B**, Lopez M, Yoav G, Lawton A, Moore G, Pratt D, Epstein M, Knox T. Absolute CD4 T-cell subsets are decreased in HIV-seronegative patients with cirrhosis [Abstract 557]. In: Program and Abstracts of the 54th Annual Meeting of the American Association for the Study of Liver Diseases (Boston) 2003.
 11. Gandhi R, Wurcel A, **McGovern B**, Lee H, Boczanowski B, Gerwin R, Corcoran C, Szczepiorkowski Z, Toner S, Giachetti C. Low prevalence of hepatitis B viremia in HIV+ individuals with isolated antibody to hepatitis B core antigen (anti-HBc) [Abstract 601]. In: Programs and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego) 2003.
 12. Wong JB, **McGovern B**, Sulkowski M, Dieterich DT, Poynard T. Projecting the prognosis of hepatic fibrosis in HIV-HCV co-infection [Abstract 551]. In: Programs and Abstracts at the 54th Annual Meeting of the American Association for the Study of Liver Diseases (Boston) 2003.
 13. Wong JB, **McGovern B**, Sulkowski M, Dieterich, DT, Poynard, T. Cost-effectiveness of peginterferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-HCV co-infected patients [Abstract 103780]. In: Program and Abstracts of Digestive Disease Week (New Orleans) 2004.
 14. **McGovern B**, Bica I, Galvin S, et al. The treatment of hepatitis C enables the treatment of HIV [Abstract 862]. In Programs and Abstracts at the 42nd Meeting of the Infectious Diseases Society of America (Boston) October, 2004.
 15. **McGovern B**, Ditelberg J, Taylor L, et al. Hepatic steatosis is associated with dideoxynucleoside analogues and HCV genotype 3 in HIV/HCV co-infected patients

[Abstract]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February, 2005 in Boston, MA and AASLD Conference on Drug Induced Liver Injury September 16-18, 2005 in Atlanta, Georgia.

16. Birch CE, Bowen M, Kim, A, **McGovern B**. Feasibility of Hepatitis C interventional programs in incarcerated injection drug users. Academic and Health Policy Conference on Correctional Health Care. March 29-30, 2007, Quincy, MA
17. Birch CE, Bowen M, Kim A, **McGovern B**. Clinical manifestations of acute HCV in incarcerated injection drug users. Academic and Health Policy Conference on Correctional Health Care. March 29-30, 2007, Quincy, MA
18. Birch CE, Bowen M, Kim A, and **BH McGovern**. A prospective study of acute HCV infection among incarcerated injection drug users. Infectious Diseases Society of American October 4-7, 2007, San Diego, CA.
19. Birch CE, Kim AY, Reyor LL, Bowen, MJ, Nagami, EH, **McGovern, BH**. Rapid virologic response is common in acute hepatitis C virus infection regardless of genotype. American Association for the Study of Liver Disease, October 31-November 4th, 2008, San Francisco, CA. Abstract #1233
20. Rhee MS, Sterling RK, **McGovern, BH**, Knox T, Terrin N and Forrester, J. The effect of HIV RNA on the severity of liver disease in HIV-infected Hispanics. American Association for the Study of Liver Disease, October 31-November 4th, 2008, San Francisco, CA. Abstract #1345
21. Schulze zur Wiesch, J, Kasprowicz, V, Kuntzen, T, Nolan, B, Longworth, S, Reyor, L, **McGovern, BH**, Allen, et al. Ex vivo analysis of CD4+ T Helper Cell Responses in Acute HCV infection and early treatment: early antiviral therapy preserves virus specific CD4+ cells. American Association for the Study of Liver Disease, October 31-November 4th, 2008, San Francisco, CA. Abstract #206
22. **McGovern BH**, Nagami E, Birch CE, et al. Improving the diagnosis of acute hepatitis C virus infection using expanded viral load criteria. Presented at the 13th International Symposium on Viral Hepatitis and Liver Disease, March 20-24, 2009, Washington, D.C. Abstract #170.
23. Kim, AY, Nagami E, Bowen M, Chung RT, **McGovern B**. A simple strategy to screen for acute HCV infection among newly incarcerated injection drug users. Submitted to the Infectious Diseases Society of America meeting 2009.
24. Bowman, S, **McGovern, BH**, Chapman, S, Zaller, N, Stein, M, Cioe, P. Taylor, LE. Hepatitis C Virus Treatment for HIV/HCV Coinfected Genotype 1 Individuals on Methadone Maintenance in Rhode Island, USA. Presented at the First International Symposium on Hepatitis Care in Injection Drug Users, Zurich, Switzerland, September 24-25, 2009; Abstract #P9.

25. Kim, A, Hill-Evans, K, Nagami, EH, Reyor, LL, Wurcel, A, **McGovern, BH**. Racial differences in drug use behaviors and risk for HCV infection among Massachusetts inmates. Presented at the 61st meeting of the Association for the Study of Liver Diseases, October 29-November 2, 2010, Boston, Massachusetts.
26. Kim, A, Hill-Evans, K, Nagami, EH, Reyor, LL, Wurcel, A, **McGovern, BH**. Racial differences in drug use behaviors and risk for HCV infection among Massachusetts inmates. Oral presentation for the 4th Academic and Health Policy Conference on Correctional Health, Boston, March 10-11, 2011

Invited Lectures:

- 2003 Gastroenterology Grand Rounds at Brigham and Women’s Hospital, Boston, MA: “Evaluation and Management of HIV/HCV Co-infection”
- Hepatitis C: Treatment of Difficult Populations at Dartmouth Medical Center, Dartmouth, NH: “Treatment of HIV-Infected Patients with Hepatitis C”
- Plenary Session of the Infectious Diseases Society of America in San Diego, California: “The Management of the HIV/HCV Co-Infected Patient”
- National Institutes of Health Conference on Treatment of Intravenous Drug Users with Hepatitis C; November, 2003 “Models of Delivery of Hepatitis C Therapy: Directly Observed Therapy”
- Medical Grand Rounds at Baystate Medical Center, Springfield, MA: “Treatment of Hepatitis C in the HIV-Infected Patient”
- 2004 HIV Grand Rounds at Massachusetts General Hospital, Boston, MA: “An Update on the Management of the HIV/HCV Co-Infected Patient”
- Medical Grand Rounds at New Bedford Hospital, New Bedford, MA, “Update on the Management of the HCV-Infected Patient”
- National Institute of Drug Abuse Symposium on the Treatment of HIV and HCV: Lecturer: “Medical Complexities of Managing the HIV/HCV Co-Infected Patient, Washington, DC, April 2004.

Medical Grand Rounds at St. Luke's Hospital, New Bedford, MA
"Hepatitis C from an Infectious Disease Standpoint."

Seminar for Correctional Health Care Providers at the University of Massachusetts Medical School: "Treatment of the HIV/HCV Co-Infected Patient in Prison"

Annual HIV Symposium at JFK Library sponsored by the Massachusetts Department of Public Health and Lemuel Shattuck Hospital: "Delivering Hepatitis C Treatment to Incarcerated HIV-Infected Patients"

Infectious Diseases Society of America: Meet the Professor Lecture Series: "Hepatitis A to E", October 2004, Boston MA.

2005 Gastroenterology Grand Rounds at Tufts-New England Medical Center, Boston, MA: "Hepatic Steatosis and Fibrosis Progression in Patients with HIV/HCV"

Gastroenterology Grand Rounds at Massachusetts General Hospital, Boston, MA: "HAART and Hepatotoxicity"

Infectious Diseases Grand Rounds at Vanderbilt Hospital, Nashville, TN: "HIV and HCV: Double Trouble"

International AIDS Society Annual Conference in Chicago, IL: "HAART and Hepatotoxicity"

Hepatitis C Foundation International, Annual Conference in Chicago IL: "Care of the HIV-infected Patient with Hepatitis C"

Infectious Disease Grand Rounds at St. Vincent's Hospital, New York, NY: "HIV and HCV: Double Trouble".

2006 The Second International HIV/HCV Conference, Amsterdam: "Treatment of Incarcerated Patients with Hepatitis C"

Annual Meeting of Gastroenterologists, Providence Rhode Island: "Hepatitis B From an ID Perspective" and "The Treatment of Hepatitis B in the HIV-infected Patient".

The New York HIV Management Course in Manhattan, NY: "Hepatotoxicity in HIV-infected Patients"

Annual HIV symposium: Sponsored by the Massachusetts Department of Public Health and Lemuel Shattuck Hospital. "Acute hepatitis C in

incarcerated populations” presented at the John F. Kennedy Library, Boston, MA

National Institutes of Health HIV/HCV Research Symposium: “Diagnosis and Screening of Hepatitis C in the HIV-infected Patient” September 2006 in Jackson Hole, Wyoming.

Satellite symposium at International Conference of Antimicrobial Agents and Chemotherapy: “Managing ART in the Co-infected Patient” September 27, 2006, San Francisco, CA

HIV Symposium, sponsored by Baystate Medical Center, “Optimizing Treatment Outcomes for Hepatitis C in HIV-infected Patients” in Baystate, Massachusetts, November 10, 2006.

2007 Academic and Health Policy Conference on Correctional Health Care, “Acute Hepatitis C in Incarcerated Injection Drug Users, March 29-30, 2007, Quincy, Massachusetts.

Infectious Disease Grand Rounds, University of Massachusetts Medical Center: “Update on Management of HIV/HCV Coinfection” in Worcester, Massachusetts, April 27, 2007.

The Ray Koff Lectureship, Metro West Hospital: “New concepts in HCV and implications for HIV/HCV co-infected patients” in Framingham, Massachusetts; May 15, 2007.

2008 Academic and Health Policy Conference on Correctional Health Care: “Rapid virologic responses in inmates with acute hepatitis C infection” on March 27-28, 2008, Quincy, MA

Fourth International Conference on HIV and Liver Disease, Plenary talk “Is steatohepatitis the next monster in the closet?” in Madrid, Spain, June 2008.

World Hepatitis C Day sponsored by the Massachusetts Department of Public Health: “Predictors of Treatment Response in Acute and Chronic Hepatitis C” in Worcester, MA, May 2008.

HIV and Liver Disease Conference, sponsored by the National Institutes of Health: “Treatment of Hepatitis B in the HIV-infected Patient” in Jackson Hole, Wyoming, September 25-27 2008.

American Association for the Study of Liver Disease: Oral research presentation: “Rapid virologic response is common in acute hepatitis C virus infection regardless of genotype”, San Francisco, CA, November 1st, 2008, Presentation #90

2009 New York HIV Management Course: “Is hepatic steatosis the next “monster in the closet?” in Manhattan, New York, May 16, 2009.

HIV Conference at Massachusetts General Hospital; “Is hepatic steatosis the next “monster in the closet?” Boston, MA, June 5, 2009.

NY Correctional Conference sponsored by Mount Sinai: “The diagnosis and treatment of acute hepatitis C infection within prisons and jails” presented at Hofstra University, September 10, 2009.

2010 Infectious Disease Grand Rounds: “Preparing for a New Era in Hepatitis C Treatment in the HIV-infected Patient” at Brigham & Women’s Medical Center, Boston, MA, April 2010.

HCV Translational Symposium at Digestive Diseases Week: “Management of the HIV/HCV Co-infected Patient” New Orleans, LA May 3, 2010.

Infectious Disease Grand Rounds: Sponsored by New England AIDS Education and Training Center: “Preparing for the era of STAT-C agents” at UMass Medical Center, July 21, 2010.

Meet the Professor luncheon: 61st meeting of the American Association for the Study of Liver Diseases; Session Title: “Hepatitis viruses and HIV: Update on Management”, Boston, MA October 30th, 2010.

2011 International Conference on Viral Hepatitis sponsored by International Association Physicians in AIDS Care (IAPAC); Keynote speaker for opening plenary talk “Viral hepatitis in the era of potent antiretroviral therapy”, Johns Hopkins Medical Center, Baltimore, MD, April 11-12 2011.

HCV: The Changing Paradigm sponsored by Center for Drug Abuse and AIDS Research: “Preparing the HIV-infected patient with HCV infection for STAT-C therapy”, Providence, Rhode Island, April 27, 2011.

Annual British HIV Conference: Opening plenary talk on “Viral Hepatitis in the Era of Potent Antiretroviral therapy” at the St. George Conference Center, London, England on November 17, 2011.

2012 Meet the Professor at the NY HIV Management Course: “Acute Hepatitis C Infection” sponsored by Mount Sinai Medical Center, Manhattan, New York, May 2012.

(b) (4)

Invited panelist:

Invited panelist for International Conference on Viral Hepatitis, sponsored by International Association for Physicians in AIDS Care (IAPAC): “Treatment issues in new era of HCV agents”, Johns Hopkins Medical Center, Baltimore, MD, April 11-12, 2011.

Invited Panelist for the Infectious Diseases Society of America: “Hepatitis C in Clinical Practice”, Boston, Massachusetts, October, 21 2011.

Invited moderator:

Session 24: Interplay of Immune Responses, Treatment, and Outcomes in Hepatitis Virus Co-Infections at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009.

“Hepatitis in Clinical Practice: An Interactive Symposium: the 47th Annual Meeting of the Infectious Diseases Society of America October 31st, 2009.

Invited teaching professorship

All-day visiting professorship to campuses of Albert Einstein and Montefiore Medical Center focused on “HIV and Liver Disease” including meetings with fellows; clinical care conference, April 28, 2010.

Invited Co-Chairperson

Co-Chairperson for all-day conference on Hepatitis C Virus Infection at Massachusetts General Hospital, April 2012